CC
AVDL

Centiva Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Centiva Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78,317
Closed -$613K – 1525
2025
Q1 		$613K Buy
+78,317
New +$656K 0.02% 717

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's AVDL Position: Q2 2025 in Review

Centiva Capital sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 78,317 shares — an estimated $613K sold.

Centiva Capital first reported a position in AVDL in Q1 2025 and held it in 1 quarter. The position peaked at $613K in Q1 2025. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Centiva Capital reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 78,317 Avadel Pharmaceuticals shares in Q2 2025, an estimated $613K.
  • Centiva Capital first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Centiva Capital's Avadel Pharmaceuticals position peaked at $613K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.